Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
Drug policy of the United Kingdom treatment. It has been argued that the main legal innovations between 1925 and 1964 were in response to international pressures, not domestic problems. In the 1960s a few doctors prescribed large amounts of heroin, some of which was diverted into the illegal market. Also substances such as cannabis, amphetamines and LSD started to become significant in the UK. In 1961 the international Single Convention on Narcotic Drugs was introduced. To control global drug trading and use, it banned countries from treating addicts by prescribing illegal substances, allowing only scientific and medical uses of drugs. It was not itself binding on